Akero Therapeutics To Present Results From Phase 2b Expansion Cohort Of SYMMETRY Trial Evaluating Efruxifermin In Combination With GLP-1
Portfolio Pulse from Happy Mohamed
Akero Therapeutics will present results from Cohort D of the Phase 2b SYMMETRY study on June 5, evaluating the safety and tolerability of efruxifermin (EFX) in combination with GLP-1 receptor agonist in patients with Type 2 diabetes and F1-F3 liver fibrosis due to NASH.
June 01, 2023 | 8:33 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Akero Therapeutics will present results from the Phase 2b SYMMETRY trial on June 5, which may impact the stock price depending on the outcome.
The presentation of the Phase 2b SYMMETRY trial results on June 5 may impact Akero Therapeutics' stock price, as investors will be closely watching the outcome. Positive results may lead to an increase in stock price, while negative results may cause a decline. However, the exact impact cannot be predicted at this time.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 100